COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine.
Virol Sin
; 35(6): 685-698, 2020 Dec.
Article
in English
| MEDLINE | ID: covidwho-807530
ABSTRACT
The World Health Organization (WHO) has declared coronavirus disease 2019 (COVID-19) is the first pandemic caused by coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, there is no effective anti-SARS-CoV-2 drug approved worldwide for treatment of patients with COVID-19. Therapeutic options in response to the COVID-19 outbreak are urgently needed. To facilitate the better and faster development of therapeutic COVID-19 drugs, we present an overview of the global promising therapeutic drugs, including repurposing existing antiviral agents, network-based pharmacology research, antibody development and traditional Chinese medicine. Among all these drugs, we focus on the most promising drugs (such as favipiravir, tocilizumab, SARS-CoV-2 convalescent plasma, hydroxychloroquine, Lianhua Qingwen, interferon beta-1a, remdesivir, etc.) that have or will enter the final stage of human testing-phase III-IV clinical trials.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
SARS-CoV-2
/
COVID-19
/
COVID-19 Drug Treatment
/
Medicine, Chinese Traditional
/
Antibodies, Viral
Type of study:
Prognostic study
Topics:
Traditional medicine
Limits:
Animals
/
Humans
Language:
English
Journal:
Virol Sin
Journal subject:
Virology
Year:
2020
Document Type:
Article
Affiliation country:
S12250-020-00297-0
Similar
MEDLINE
...
LILACS
LIS